| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027 |
| 28 Oct 2026 |
8-K: Other Events
Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 |
| 14 Jul 2026 |
8-K: Other Events
First-in-disease therapies for patients with rare diseases Corporate Presentation July 2026 |
| 30 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 29, 2026 (the “Appointment Date”), the Board of Directors (the “Board”) of Palvella Therapeutics, Inc. (the “Company”) increased the size of the Board from seven to eight members and, upon recommendation of the Nominating and Cor... |
| 16 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
WHEREAS, Palvella Therapeutics, Inc. (the “Company”) maintains the Palvella Therapeutics, Inc. 2024 Equity Incentive Plan (the “Plan”), which was previously adopted by the Board of Directors of the Company (the “Board”) and approved by t... |
| 20 May 2026 |
8-K: Other Events
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare ... |
| 15 May 2026 |
8-K: Other Events
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology |
| 13 May 2026 |
8-K: Other Events
On May 11, 2026, Palvella Therapeutics, Inc. (the “Company”) received approval from the Nasdaq Listing Qualifications Department to move the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Market, effectiv... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on track for second half of 2026 |
| 13 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 13, 2026 (the “Appointment Date”), the Board of Directors (the “Board”) of Palvella Therapeutics, Inc. (the “Company”) increased the size of the Board from six to seven members and, upon recommendation of the Nominating and Corp... |
| 07 Apr 2026 |
8-K: Other Events
First-in-disease therapies for patients with rare diseases Corporate Presentation April 2026 |
| 31 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
New Drug Application (NDA) for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on track for planned submission in second half of 2026 |
| 26 Feb 2026 |
8-K: Entry into a Material Definitive Agreement
TD Securities (USA) LLC Cantor Fitzgerald & Co. Stifel, Nicolaus & Company, Incorporated |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition
On February 24, 2026, Palvella Therapeutics, Inc. (the “Company”) announced that, as of December 31, 2025, the Company had approximately $55.9 million of cash, cash equivalents and marketable securities. The Company has not yet completed... |
| 24 Feb 2026 |
8-K: Regulation FD Disclosure
First-in-disease therapies for patients with rare diseases Phase 3 SELVA Topline Data in Microcystic Lymphatic Malformations February 24, 2026 |
| 24 Feb 2026 |
8-K: Other Events
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations |
| 29 Jan 2026 |
8-K: Other Events
First-in-disease therapies for patients with rare diseases Corporate Presentation January 2026 |
| 12 Jan 2026 |
8-K: Other Events
First-in-disease therapies for patients with rare diseases Corporate Presentation January 2026 |
| 15 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease w... |
Loading...